soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Heart disease is the #1 cause of death in type 2 diabetes — and for the first time, an GLP-1 drug has been proven to reduce major events The Oral Semaglutide and Cardiovascular Outcomes

312.312.7873

But when it comes to satisfying key consumer trends, two major stumbling blocks are holding the market back: its difficult to add lots of protein without a negative impact on texture, and its tricky to create cereal bars that are not high in sugar.

Manufacturers of medications, such as well-known weight-loss medications like Wegovy, are required by law to warn patients and healthcare professionals of any possible hazards

In conclusion, GLP-1 RAs are an intriguing multitarget treatment option for people with NDs, and future research should focus on optimizing treatment for clinical trials, evolved agonists that can penetrate the central nervous system (CNS), and combination therapies.

New research suggests people taking these medications may not be getting enough guidance on protein, vitamins, and overall diet quality, increasing the risk of muscle loss and nutrient deficiencies.